Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

The Dermatology Digest

MARCH 17, 2025

has enrolled of the first patient in a Phase 2 trial of EVO301, an injectable interleukin (IL)-18 neutralizer, in moderate-to-severe atopic dermatitis (AD). EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis. Evommune, Inc.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

Dermatology Times

SEPTEMBER 18, 2024

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

Dermatitis 41

Dermatitis Therapy 41

Dermatology Times

APRIL 11, 2024

In one study, researchers were unable to detect any changes in the gut microbiome of patients treated with tapering dose of steroids or a probiotic mixture.

Dermatitis 81

Dermatitis Therapy 81

Dermatology Times

DECEMBER 24, 2024

James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.

Dermatitis 36

Dermatitis Therapy Treatments 36

First Derm

JUNE 10, 2024

Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.

Dermatitis 45

Dermatitis Irritation Eczema Dry Skin 45

Dermatology Times

OCTOBER 27, 2024

At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.

Dermatitis 53

Dermatitis Treatments Therapy Management 53

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance. The study appears in Dermatitis.

Treatments 77

Treatments Dermatitis Therapy Medical 77

Dermatology Times

MARCH 4, 2024

Test your knowledge on the AAD's recommendations for phototherapy, monoclonal antibodies, JAK inhibitors, and systemic therapies in the latest guidelines.

Dermatitis 73

Dermatitis Therapy 73

The Dermatology Digest

DECEMBER 11, 2024

pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The most common (>5%) AEs observed were nasopharyngitis, atopic dermatitis and headache. AnaptysBio, Inc.is

Safety 36

Safety Dermatitis Therapy Dermatology 36

Dermatology Times

DECEMBER 12, 2023

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

Dermatitis 74

Dermatitis Therapy 74

Dermatology Times

AUGUST 27, 2024

The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.

Dermatitis 45

Dermatitis Treatments Therapy 45

Dermatology Times

FEBRUARY 28, 2025

Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.

Dermatitis 36

Dermatitis Therapy Treatments 36

First Derm

FEBRUARY 21, 2024

Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?

Eczema 59

Eczema Dermatitis Management Medical 59

Dermatology Times

FEBRUARY 17, 2024

Investigators revealed the development of a non-invasive molecular test utilizing gene expression differences in skin diseases such as atopic dermatitis, psoriasis, and mycosis fungoides, with the potential to accurately diagnose and identify super-responders to targeted systemic therapies.

Dermatitis 87

Dermatitis Therapy 87

The Dermatology Digest

FEBRUARY 27, 2025

The nine recipients of the National Eczema Association (NEA) 2024 research grant cycle are Champion Research Grant Encourages proven researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema. NEA has now invested more than$4.4 millionsince its first grant was awarded in 2004.

Eczema 36

Eczema Dermatitis Hospital Office 36

Dermatology Times

DECEMBER 7, 2023

A patient returns to your clinic seeking systemic therapy for her AD while postpartum and breastfeeding. Test your knowledge on injectables.

Management 73

Management Dermatitis Injections Therapy 73

Alison Bladh

JANUARY 1, 2025

Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

JANUARY 13, 2025

Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

Dermatology Times

MARCH 6, 2025

The panelist discusses how to evaluate the need for and manage the transition between biologic therapies in a 32-year-old woman with severe atopic dermatitis who has had an inadequate response to initial treatment.

Dermatitis 36

Dermatitis Therapy Management Treatments 36

Dermatology Times

OCTOBER 3, 2023

As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.

Social Media 74

Social Media Dermatitis Therapy 74

The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

Dermatology Times

FEBRUARY 19, 2025

Alphyns therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

Dermatitis 72

Dermatitis Therapy 72

Dermatology Times

JANUARY 8, 2024

The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.

Dermatitis 80

Dermatitis Therapy 80

Dermatology Times

DECEMBER 11, 2023

From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.

Management 73

Management Dermatitis Therapy 73

Dermatology Times

JANUARY 8, 2025

Experts explore innovative therapies, psychosocial impacts, and education strategies for managing atopic dermatitis in a Dermatology Times video series.

Dermatitis 41

Dermatitis Innovations Education Therapy 41

Dermatology Times

DECEMBER 27, 2024

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in atopic dermatitis this year.

Dermatitis 41

Dermatitis Dermatology Therapy 41

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

Dermatology Times

MARCH 14, 2025

Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.

Safety 36

Safety Dermatitis Therapy 36

Dermatology Times

MAY 30, 2024

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative. (..)

Dermatitis 72

Dermatitis Therapy Management Treatments 72

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. In the lower dose group, 36.3% of patients achieved EASI-75, a 23.4%

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

FEBRUARY 10, 2025

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. “We are pleased that rezpegaldesleukin has been designated a Fast Track product,” says Jonathan Zalevsky, Ph.D.,

Dermatitis 36

Dermatitis Therapy Office Safety 36

The Dermatology Digest

APRIL 1, 2025

Targeted therapies against type 2 inflammation are revolutionizing the treatment of these three conditions that until now were very difficult to treat and had tremendous impact on those who suffered from them. The new targeted biologic therapies that target IL4 and IL13, among others, are revolutionizing the treatment of these conditions.

Dermatitis 36

Dermatitis Dermatology Therapy Tools 36

Dermatology Times

FEBRUARY 18, 2025

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.

Dermatology 68

Dermatology Dermatitis Therapy Treatments 68

Dermatology Times

MARCH 14, 2025

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

Dermatitis 36

Dermatitis Safety Education Therapy 36

Dermatology Times

AUGUST 9, 2024

Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.

Dermatitis 41

Dermatitis Treatments Therapy 41